Abstract: A lipstick storage assembly includes a housing that has an opening to access a plurality of discrete lipstick spaces. Each of the discrete lipstick spaces insertably receives a tube of lipstick. A base is movably coupled to the housing. An extender is positioned within the base. The extender urges a selected one of the tubes of lipstick upwardly in the discrete lipstick spaces. The extender is in mechanical communication with the base. The base is rotatable relative to the housing such that the extender engages the selected tube of lipstick.

Abstract: A method for treating psoriasis. An antagonist to IL-17D?9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17D?9 or its receptor or a soluble receptor that binds to IL-17D?9 or a membrane-spanning protein-5 (MSP-5).

Abstract: IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in order to accelerate the wound healing process. The present invention further encompasses a pharmaceutical composition and formulations thereof that utilize IL-17B, either alone or in combination with other cytokines or growth factors known to aid wound healing. The invention also contemplates methods of treating wounds in patients using this pharmaceutical composition.

Abstract: A method for treating psoriasis. An antagonist to IL-17D?9 (IL-17D) is administered to treat psoriasis. The antagonist can be an antibody that binds to IL-17D?9 or its receptor or a soluble receptor that binds to IL-17D?9 or a membrane-spanning protein-5 (MSP-5).

Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.